9-benzhydryloxy-7-(4-fluoro-benzyl)-5-hydroxy-6,7-dihydro-pyrrolo[3,4-g]quinolin-8-one | 684284-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-benzhydryloxy-7-(4-fluoro-benzyl)-5-hydroxy-6,7-dihydro-pyrrolo[3,4-g]quinolin-8-one
• 英文别名: 9-benzhydryloxy-7-[(4-fluorophenyl)methyl]-5-hydroxy-6H-pyrrolo[3,4-g]quinolin-8-one
• CAS: 684284-67-1
• 化学式: C₃₁H₂₃FN₂O₃
• 分子量: 490.534
• InChiKey: KQTRHWZFIABGAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  9-benzhydryloxy-7-(4-fluoro-benzyl)-5-hydroxy-6,7-dihydro-pyrrolo[3,4-g]quinolin-8-one 在 palladium diacetate 、 TEA 、 1,3-双(二苯基膦)丙烷 、 caesium carbonate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.25h， 生成 9-benzhydryloxy-7-(4-fluoro-benzyl)-8-oxo-7,8-dihydro-6H-pyrrolo[3,4-g]quinoline-5-carboxylic acid
  参考文献：
  名称：

  Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors

  摘要：

  A novel class of tri-cyclic HIV integrase inhibitors were designed based on conformational analysis of 1,6-naphthyridine carboxamide compound L-870810 and docking the designed inhibitor into the active site of our integrase enzyme model. The efficient syntheses of pyrroloquinoline tri-cyclic analogs are described. The SAR studies resulted in the identification of a lead compound that is more potent and more soluble than L-870810. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.016
• 作为产物：
  描述：

  [9-Benzhydryloxy-7-[(4-fluorophenyl)methyl]-6,8-dioxopyrrolo[3,4-g]quinolin-5-yl] ethyl carbonate 在 4-二甲氨基吡啶 、 锂硼氢 、 四丁基氟化铵 、 potassium carbonate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 40.0h， 生成 9-benzhydryloxy-7-(4-fluoro-benzyl)-5-hydroxy-6,7-dihydro-pyrrolo[3,4-g]quinolin-8-one
  参考文献：
  名称：

  Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors

  摘要：

  A novel class of tri-cyclic HIV integrase inhibitors were designed based on conformational analysis of 1,6-naphthyridine carboxamide compound L-870810 and docking the designed inhibitor into the active site of our integrase enzyme model. The efficient syntheses of pyrroloquinoline tri-cyclic analogs are described. The SAR studies resulted in the identification of a lead compound that is more potent and more soluble than L-870810. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.05.016

文献信息

• Integrase inhibitor compounds
  申请人：Cai R. Zhenhong

  公开号：US20070072831A1

  公开（公告）日：2007-03-29

  Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  三环化合物、其受保护的中间体以及用于抑制HIV整合酶的方法被披露。
• Phosphonate analogs of HIV integrase inhibitor compounds
  申请人：Cai R. Zhenhong

  公开号：US20060116356A1

  公开（公告）日：2006-06-01

  Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  本发明揭示了至少具有一个膦酸酯基团的新型HIV整合酶抑制剂化合物，其保护中间体以及用于抑制HIV整合酶的方法。
• Pre-organized tricyclic integrase inhibitor compounds
  申请人：GILEAD SCIENCES, INC.

  公开号：US20040157804A1

  公开（公告）日：2004-08-12

  Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. 1 A 1 and A 2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl. Q is N, + NR, or CR 4 . The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.

  本发明揭示了以下结构的三环化合物、其保护中间体以及抑制HIV整合酶的方法。其中，1A1和A2是形成五、六或七元环的基团。L是连接Ar环原子和N原子的键或连接器。X为O、S或取代氮。Ar为芳基或杂环芳基。Q为N、+NR或CR4。芳基碳可以独立地被取代为除氢以外的取代基。化合物可以包括共价连接在任何位点的前药基团。
• Antiviral compounds
  申请人：Cai Zhenhong R.

  公开号：US20080076740A1

  公开（公告）日：2008-03-27

  The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及磷取代的抗病毒抑制化合物、含有该化合物的组合物、包括给予该化合物的治疗方法，以及用于制备该化合物的有用过程和中间体。
• Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
  申请人：Cai R. Zhenhong

  公开号：US20080076738A1

  公开（公告）日：2008-03-27

  Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

  本发明公开了至少具有一个膦酸酯基团的新型HIV整合酶抑制剂化合物、其受保护的中间体以及用于抑制HIV整合酶的方法。